322 related articles for article (PubMed ID: 31920295)
1. Efficacy and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD: A Subgroup Analysis of the KRONOS Study.
Ichinose M; Fukushima Y; Inoue Y; Hataji O; Ferguson GT; Rabe KF; Hayashi N; Okada H; Takikawa M; Bourne E; Ballal S; DeAngelis K; Aurivillius M; Dorinsky P; Reisner C
Int J Chron Obstruct Pulmon Dis; 2019; 14():2979-2991. PubMed ID: 31920295
[TBL] [Abstract][Full Text] [Related]
2. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial.
Ferguson GT; Rabe KF; Martinez FJ; Fabbri LM; Wang C; Ichinose M; Bourne E; Ballal S; Darken P; DeAngelis K; Aurivillius M; Dorinsky P; Reisner C
Lancet Respir Med; 2018 Oct; 6(10):747-758. PubMed ID: 30232048
[TBL] [Abstract][Full Text] [Related]
3. Long-Term Safety and Efficacy of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD.
Ichinose M; Fukushima Y; Inoue Y; Hataji O; Ferguson GT; Rabe KF; Hayashi N; Okada H; Takikawa M; Bourne E; Ballal S; DeAngelis K; Aurivillius M; Reisner C; Dorinsky P
Int J Chron Obstruct Pulmon Dis; 2019; 14():2993-3002. PubMed ID: 31920296
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler in Chinese Patients with COPD: A Subgroup Analysis of KRONOS.
Wang C; Yang T; Kang J; Chen R; Zhao L; He H; Assam PN; Su R; Bourne E; Ballal S; DeAngelis K; Dorinsky P
Adv Ther; 2020 Apr; 37(4):1591-1607. PubMed ID: 32152869
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of budesonide/glycopyrronium/formoterol metered dose inhaler in patients with COPD: post-hoc analysis from the KRONOS study excluding patients with airway reversibility and high eosinophil counts.
Muro S; Sugiura H; Darken P; Dorinsky P
Respir Res; 2021 Jun; 22(1):187. PubMed ID: 34182998
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler formulated using co-suspension delivery technology after single and chronic dosing in patients with COPD.
Dunn LJ; Kerwin EM; DeAngelis K; Darken P; Gillen M; Dorinsky P
Pulm Pharmacol Ther; 2020 Feb; 60():101873. PubMed ID: 31841699
[TBL] [Abstract][Full Text] [Related]
7. A Randomized, Double-Blind, Double-Dummy Study of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Relative to Umeclidinium/Vilanterol Dry Powder Inhaler in COPD.
Maltais F; Ferguson GT; Feldman GJ; Deslee G; Bourdin A; Fjällbrant H; Siwek-Posłuszna A; Jenkins MA; Martin UJ
Adv Ther; 2019 Sep; 36(9):2434-2449. PubMed ID: 31267366
[TBL] [Abstract][Full Text] [Related]
8. A phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6 μg and 160/18/9.6 μg using co-suspension delivery technology in moderate-to-very severe COPD: The ETHOS study protocol.
Rabe KF; Martinez FJ; Ferguson GT; Wang C; Singh D; Wedzicha JA; Trivedi R; St Rose E; Ballal S; McLaren J; Darken P; Reisner C; Dorinsky P
Respir Med; 2019; 158():59-66. PubMed ID: 31605923
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β
Ferguson GT; Darken P; Ballal S; Siddiqui MK; Singh B; Attri S; Holmgren U; de Nigris E
Adv Ther; 2020 Jun; 37(6):2956-2975. PubMed ID: 32335859
[TBL] [Abstract][Full Text] [Related]
10. Functional respiratory imaging assessment of budesonide/glycopyrrolate/formoterol fumarate and glycopyrrolate/formoterol fumarate metered dose inhalers in patients with COPD: the value of inhaled corticosteroids.
van den Berge M; De Backer J; Van Holsbeke C; De Backer W; Trivedi R; Jenkins M; Dorinsky P; Aurivillius M
Respir Res; 2021 Jul; 22(1):191. PubMed ID: 34210340
[TBL] [Abstract][Full Text] [Related]
11. Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Exacerbation Outcomes in Patients with COPD without a Recent Exacerbation History: A Subgroup Analysis of KRONOS.
Martinez FJ; Ferguson GT; Bourne E; Ballal S; Darken P; Aurivillius M; Dorinsky P; Reisner C
Int J Chron Obstruct Pulmon Dis; 2021; 16():179-189. PubMed ID: 33542624
[TBL] [Abstract][Full Text] [Related]
12. Bone and ocular safety of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a 52-week randomized study.
Kerwin EM; Ferguson GT; Mo M; DeAngelis K; Dorinsky P
Respir Res; 2019 Jul; 20(1):167. PubMed ID: 31358008
[TBL] [Abstract][Full Text] [Related]
13. Benefits of glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) in improving lung function and reducing exacerbations in patients with moderate-to-very severe COPD: a pooled analysis of the PINNACLE studies.
Martinez FJ; Lipworth BJ; Rabe KF; Collier DJ; Ferguson GT; Sethi S; Feldman GJ; O'Brien G; Jenkins M; Reisner C
Respir Res; 2020 May; 21(1):128. PubMed ID: 32450869
[TBL] [Abstract][Full Text] [Related]
14. Improvements in lung function with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler
Rabe KF; Martinez FJ; Singh D; Trivedi R; Jenkins M; Darken P; Aurivillius M; Dorinsky P
Ther Adv Respir Dis; 2021; 15():17534666211034329. PubMed ID: 34428980
[TBL] [Abstract][Full Text] [Related]
15. Efficacy And Safety Of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (GFF MDI) Formulated Using Co-Suspension Delivery Technology In Chinese Patients With COPD.
Chen R; Zhong N; Wang HY; Zhao L; Mei X; Qin Z; Huang J; Assam PN; Maes A; Siddiqui S; Martin UJ; Reisner C
Int J Chron Obstruct Pulmon Dis; 2020; 15():43-56. PubMed ID: 32021143
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler delivered using co-suspension delivery technology in Japanese patients with moderate-to-very severe chronic obstructive pulmonary disease.
Gon Y; Nishi K; Sato K; Maes A; Siddiqui S; Hayashi N; Hirata H; Martin UJ; Reisner C
Respir Investig; 2021 Jan; 59(1):135-144. PubMed ID: 32917556
[TBL] [Abstract][Full Text] [Related]
17. The pharmacokinetics of three doses of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler compared with active controls: A Phase I randomized, single-dose, crossover study in healthy adults.
Darken P; DePetrillo P; Reisner C; St Rose E; Dorinsky P
Pulm Pharmacol Ther; 2018 Jun; 50():11-18. PubMed ID: 29544728
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and Tolerability of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate and Glycopyrronium/Formoterol Fumarate Dihydrate Metered Dose Inhalers in Healthy Chinese Adults: A Randomized, Double-blind, Parallel-group Study.
Chen Q; Hu C; Yu H; Shen K; Assam PN; Gillen M; Liu Y; Dorinsky P
Clin Ther; 2019 May; 41(5):897-909.e1. PubMed ID: 30982547
[TBL] [Abstract][Full Text] [Related]
19. Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Lung Function versus Monotherapies in GOLD Category A Patients with COPD: Pooled Data from the Phase III PINNACLE Studies.
Martinez FJ; Rabe KF; Lipworth BJ; Arora S; Jenkins M; Martin UJ; Reisner C
Int J Chron Obstruct Pulmon Dis; 2020; 15():99-106. PubMed ID: 32021148
[TBL] [Abstract][Full Text] [Related]
20. Improved lung function and patient-reported outcomes with co-suspension delivery technology glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a randomized Phase III study conducted in Asia, Europe, and the USA.
Lipworth BJ; Collier DJ; Gon Y; Zhong N; Nishi K; Chen R; Arora S; Maes A; Siddiqui S; Reisner C; Martin UJ
Int J Chron Obstruct Pulmon Dis; 2018; 13():2969-2984. PubMed ID: 30310273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]